Health
SARS-CoV-2 Neucleocapside (N) protein is heavily glycosylated – News-Medical.Net
However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint server bioRxiv in August 2020 reveals the structure of this protein, a val…
Eight months into the COVID-19 pandemic, there is still no fully protective therapy against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has infected millions worldwide. Vaccines are being worked on in a host of institutions and countries, mostly targeting the spike protein of the virus. However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint s…
-
Noosa News12 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business16 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business12 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General22 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts